CV Sciences Common Stock Net 2011-2024 | CVSI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CV Sciences common stock net from 2011 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CV Sciences common stock net from 2011 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$87.5B
Takeda Pharmaceutical (TAK)	$47.5B
Merck (MKGAF)	$24.4B
Astellas Pharma (ALPMY)	$22B
Sandoz Group AG (SDZNY)	$17.6B
Summit Therapeutics (SMMT)	$16.8B
United Therapeutics (UTHR)	$15.6B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$12.2B
Catalent (CTLT)	$10.9B
Revolution Medicines (RVMD)	$7.7B
Orion OYJ (ORINY)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$4.3B
Corcept Therapeutics (CORT)	$4.3B
Dyne Therapeutics (DYN)	$3.7B
PTC Therapeutics (PTCT)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Xencor (XNCR)	$1.7B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B